Stan­ford star on­col­o­gy sci­en­tist Ed En­gle­man helped cre­ate the im­munother­a­py field. Now he wants to shake up neu­rode­gen­er­a­tion R&D

Over the last gen­er­a­tion of drug R&D, Ed En­gle­man has been a stand­out sci­en­tist.

The Stan­ford pro­fes­sor co-found­ed Den­dreon and pro­vid­ed the sci­en­tif­ic in­sights need­ed to de­vel­op Provenge in­to a pi­o­neer­ing — though not par­tic­u­lar­ly mar­ketable — im­munother­a­py. He’s spurred a slate of star­tups, as­sist­ed by his well-con­nect­ed perch as a co-founder of Vi­vo Cap­i­tal, and took the den­drit­ic cell sto­ry in­to its next chap­ter at a start­up called Bolt.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN